Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-01-05

FDA Approved: LEVETIRACETAM — Supplemental Application (ScieGen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for levetiracetam from ScieGen Pharmaceuticals, Inc. The approval pertains to the generic product in the approved ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LEVETIRACETAM (levetiracetam)

Snippet

SUPPL AP for LEVETIRACETAM (LEVETIRACETAM)